Unknown

Dataset Information

0

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.


ABSTRACT: To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to ≥1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0-100); morning stiffness (hours); modified Health Assessment Questionnaire (mHAQ; 0-3); and EuroQoL EQ-5D. Of the 667 patients who newly initiated rituximab, baseline PRO and clinical measures indicated that patients were substantially impacted by their RA disease and quality of life; 54% of patients had high disease activity. One year after rituximab initiation, 49.0, 47.1, 49.8, and 23.2% of patients reported clinically meaningful improvements in patient global, pain, fatigue, and mHAQ, respectively. Morning stiffness and EuroQol EQ-5D domains improved in 48 and 19-32% of patients, respectively. These real-world registry data demonstrated that patients with long-standing, refractory RA experienced improvements in PROs 1 year after initiating rituximab.

SUBMITTER: Harrold LR 

PROVIDER: S-EPMC5554472 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.

Harrold Leslie R LR   John Ani A   Best Jennie J   Zlotnick Steve S   Karki Chitra C   Li YouFu Y   Greenberg Jeffrey D JD   Kremer Joel M JM  

Clinical rheumatology 20170717 9


To evaluate the impact of rituximab on patient-reported outcomes (PROs) in a US-based observational cohort of patients with rheumatoid arthritis (RA). Patients with active RA, prior exposure to ≥1 tumor necrosis factor inhibitor (TNFi) and who newly initiated rituximab were identified. Changes in PROs were assessed 1 year after rituximab initiation. PRO measures included Clinical Disease Activity Index (CDAI); patient global disease activity, pain and fatigue (visual analog score; 0-100); mornin  ...[more]

Similar Datasets

| S-EPMC6108331 | biostudies-literature
| S-EPMC7991054 | biostudies-literature
| S-EPMC5604726 | biostudies-literature
| S-EPMC5696293 | biostudies-literature
| S-EPMC7316680 | biostudies-literature
| S-EPMC8869620 | biostudies-literature
| S-EPMC7211217 | biostudies-literature
| S-EPMC11492957 | biostudies-literature
| S-EPMC4999578 | biostudies-literature
| S-EPMC6421089 | biostudies-literature